How does Merck make money?

Merck & Co., Inc. – Business Breakdown

The Essentials

Merck & Co., Inc. is a global healthcare company organized around two operating pillars: Pharmaceutical and Animal Health. Its core economic engine is the discovery, development, manufacture, and commercialization of prescription medicines, vaccines, and veterinary products across global markets. The profile indicates a business of substantial scale, with FY 2025 total sales of $65.0 billion, and a revenue base that is still overwhelmingly anchored in pharmaceuticals.

The company’s industrial significance is defined by its concentration in high-value therapeutic franchises, most notably Keytruda, which alone accounts for more than half of pharmaceutical revenue. That concentration underscores both Merck’s commercial strength and its strategic fragility: the franchise is exceptionally powerful today, but it also creates meaningful exposure to patent expiry, competitive encroachment, and pricing pressure over time. Animal Health provides a smaller but useful diversification layer, with a balanced mix of livestock and companion animal products.

Business Model & Revenue Drivers

Merck monetizes scientific innovation through a portfolio model, but the revenue mix is highly uneven. The company’s economic value is driven by a small number of blockbuster products, alliance revenues, and a broad tail of other pharmaceutical and animal health offerings.

• Pharmaceutical segment

  • FY 2025 sales of $58.1 billion, representing the dominant share of group revenue.
  • Keytruda/Keytruda Qlex generated $31.7 billion, or 54.5% of pharmaceutical sales, making it the central profit driver and the clearest source of operating leverage.
  • Gardasil/Gardasil 9 contributed $5.2 billion, though sales declined sharply year over year, indicating maturity and saturation in the HPV vaccine category.
  • Januvia/Janumet produced $2.5 billion, but the profile suggests limited strategic moat in diabetes relative to newer therapies.
  • Bridion, Prevymis, and ProQuad/M-M-R II/Varivax provide additional scale, but are not the primary value drivers.
  • Alliance revenues from Lynparza and Lenvima add meaningful but structurally constrained income, since these are profit-sharing arrangements rather than wholly controlled assets.
  • Winrevair is a notable growth contributor, with rapid early penetration suggesting emerging commercial relevance.

• Animal Health segment

  • FY 2025 sales of $5.9 billion.
  • Revenue is split between Livestock Products and Companion Animal Products, with livestock representing the larger share.
  • This segment adds diversification and distribution depth, but it is not the principal earnings engine.

• Geographic mix

  • Revenue is broadly balanced between the U.S. and international markets, with international sales representing roughly half of total revenue.
  • This geographic spread provides some insulation from single-market regulatory or pricing shocks, though it does not eliminate them.

Strategic Edge & Market Positioning

Merck’s competitive position is best characterized as a moderate structural moat with clear execution risk.

Economic Moat

• Patent protection and exclusivity remain the most important structural supports, particularly for Keytruda and Gardasil.
• Clinical data depth is a meaningful barrier to entry: Keytruda’s extensive approvals across 20+ cancer indications create a formidable regulatory and evidentiary base.
• Scale and manufacturing footprint support operational efficiency and create practical switching costs, especially in biologics, vaccines, and animal health distribution.
• The company also benefits from regulatory precedent and established commercialization infrastructure.

Execution Advantage

• Merck’s current strength is heavily dependent on successful lifecycle management, line extensions, and continued clinical execution.
• Winrevair’s rapid growth demonstrates that the company can still convert innovation into commercial traction.
• The alliance structure around Lynparza and Lenvima shows Merck can participate in value creation through partnerships, but these are not proprietary moats; they are execution-dependent economic arrangements.

Moat Erosion

• The profile is explicit that Keytruda concentration is extreme, creating a major vulnerability as exclusivity approaches the mid-2030s.
• Gardasil’s decline signals weakening pricing power in a mature vaccine market.
• Januvia/Janumet appears exposed to stronger competitive therapies, limiting its strategic defensibility.
• Overall, Merck’s moat is real but not impregnable; it is increasingly reliant on pipeline renewal rather than entrenched structural dominance.

Outlook & Innovation Pipeline

Merck’s next three years appear centered on portfolio renewal, oncology expansion, and capital deployment into higher-growth therapeutic adjacencies. The strategic roadmap is clearly designed to reduce dependence on Keytruda while building the next generation of growth assets.

• Cidara Therapeutics acquisition

  • A major transaction announced in January 2026, valued at approximately $9.2 billion.
  • The deal expands Merck’s ADC / drug-conjugate capabilities and is expected to generate a substantial in-process R&D charge.
  • Strategically, this is a direct attempt to deepen the oncology pipeline and broaden the post-Keytruda growth base.

• Blackstone Life Sciences funding arrangement

  • Up to $700 million of non-refundable funding for sacituzumab tirumotecan (sac-TMT).
  • This structure reduces development risk while preserving Merck’s control, suggesting disciplined capital allocation around a high-potential ADC asset.

• Verona Pharma acquisition

  • Intended to expand Merck’s respiratory footprint through Ohtuvayre (ensifentrine).
  • This indicates a deliberate move beyond oncology into adjacent therapeutic categories.

• Hengrui Pharma license agreement

  • Provides access to MK-7262 (HRS-5346), an oral Lipoprotein(a) inhibitor in Phase 2.
  • This is strategically important because it opens a potential cardiovascular growth avenue with blockbuster characteristics.

• Pipeline focus

  • The core innovation agenda is concentrated in oncology, especially ADCs and T-cell engagers.
  • Additional emphasis is visible in cardiometabolic and respiratory programs.
  • The profile does not provide a full R&D budget for FY 2025, but it does indicate substantial investment intensity and a willingness to use acquisitions and partnerships to accelerate pipeline depth.

Overall, Merck’s outlook is defined by a classic large-cap pharma transition: a highly profitable incumbent franchise funding a deliberate search for the next wave of growth. The central question is not whether the company has scientific ambition, but whether its pipeline can mature quickly enough to offset the eventual normalization of Keytruda economics.